Beyond Medical Technologies Provides Update on 2024 Annual Filings
Beyond Medical Technologies (OTC: DOCKF) has received acceptance from the British Columbia Securities Commission (BCSC) for its management cease trade order (MCTO) application. The MCTO, effective May 1, 2025, relates to a delay in filing the company's 2024 annual financial statements and related documentation. The delay is attributed to a recent management team transition. The company expects to complete the Annual Filings by June 30, 2025 and will comply with alternative information guidelines, including bi-weekly default status updates.
Beyond Medical Technologies (OTC: DOCKF) ha ottenuto l'approvazione dalla British Columbia Securities Commission (BCSC) per la sua richiesta di ordine di sospensione del trading per la direzione (MCTO). Il MCTO, valido dal 1° maggio 2025, riguarda un ritardo nella presentazione del bilancio annuale 2024 e dei documenti correlati. Il ritardo è dovuto a un recente cambio nel team di gestione. La società prevede di completare le dichiarazioni annuali entro il 30 giugno 2025 e si impegna a rispettare le linee guida alternative sull'informazione, inclusi aggiornamenti sullo stato del default ogni due settimane.
Beyond Medical Technologies (OTC: DOCKF) ha recibido la aprobación de la Comisión de Valores de Columbia Británica (BCSC) para su solicitud de orden de suspensión comercial para la gerencia (MCTO). El MCTO, vigente a partir del 1 de mayo de 2025, está relacionado con un retraso en la presentación de los estados financieros anuales de 2024 y la documentación asociada. El retraso se atribuye a una reciente transición en el equipo directivo. La empresa espera completar las presentaciones anuales antes del 30 de junio de 2025 y cumplirá con las directrices alternativas de información, incluyendo actualizaciones quincenales sobre el estado del incumplimiento.
Beyond Medical Technologies (OTC: DOCKF)는 브리티시컬럼비아 증권위원회(BCSC)로부터 경영진 거래중지 명령(MCTO) 신청 승인을 받았습니다. 이 MCTO는 2025년 5월 1일부터 발효되며, 회사의 2024년 연례 재무제표 및 관련 서류 제출 지연과 관련이 있습니다. 지연 사유는 최근 경영진 교체 때문입니다. 회사는 연례 제출 서류를 2025년 6월 30일까지 완료할 예정이며, 격주로 기본 상태 업데이트를 포함한 대체 정보 지침을 준수할 것입니다.
Beyond Medical Technologies (OTC : DOCKF) a obtenu l'acceptation de la British Columbia Securities Commission (BCSC) pour sa demande d'ordre de suspension de négociation pour la direction (MCTO). Le MCTO, effectif à partir du 1er mai 2025, concerne un retard dans le dépôt des états financiers annuels 2024 et des documents connexes de l'entreprise. Ce retard est dû à une récente transition au sein de l'équipe de direction. La société prévoit de finaliser les dépôts annuels d'ici le 30 juin 2025 et respectera les directives d'information alternatives, incluant des mises à jour bi-hebdomadaires sur le statut de défaut.
Beyond Medical Technologies (OTC: DOCKF) hat von der British Columbia Securities Commission (BCSC) die Zustimmung für seinen Antrag auf eine Handelsaussetzung für das Management (MCTO) erhalten. Das MCTO, wirksam ab dem 1. Mai 2025, bezieht sich auf eine Verzögerung bei der Einreichung der Jahresfinanzberichte 2024 und der dazugehörigen Unterlagen des Unternehmens. Die Verzögerung ist auf einen kürzlichen Wechsel im Management-Team zurückzuführen. Das Unternehmen erwartet, die Jahresunterlagen bis zum 30. Juni 2025 abzuschließen und wird alternative Informationsrichtlinien einhalten, einschließlich zweiwöchentlicher Updates zum Status des Ausfalls.
- None.
- Delay in filing 2024 annual financial statements and related documentation
- Management cease trade order (MCTO) issued by BCSC
- Recent management team transition causing reporting delays
Vancouver, British Columbia--(Newsfile Corp. - May 2, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company") announces that its application for a management cease trade order ("MCTO") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), as previously announced in a news release dated April 16, 2025, has been accepted by the British Columbia Securities Commission (the "BCSC"). The MCTO was issued by the BCSC, effective as of May 1, 2025, in connection with the delay by the Company in filing its audited annual financial statements and accompanying management's discussion and analysis and related CEO and CFO certificates for the financial year ended December 31, 2024 (collectively, the "Annual Filings"). The delay is due to the recent transition to a new management team.
The Company expects to file the Annual Filings as soon as they are available and by no later than June 30, 2025. The Company will issue a news release once the Annual Filings have been filed. Until the Company files the Annual Filings, it will comply with the alternative information guidelines set out in NP 12-203, including the issuance of bi-weekly default status reports in the form of news releases. The Company confirms as of the date of this news release that there has been no material change in the information contained in the Company's news release issued April 16, 2025, and there is no other material information concerning the affairs of the Company that has not been generally disclosed.
About Beyond Medical Technologies Inc.
Beyond Medical Technologies Inc. is a healthcare technology company integrating blockchain infrastructure to enhance patient outcomes and operational efficiency across the medical ecosystem.
On behalf of the Board of Directors
Daniel Liu, Chief Executive Officer
Email: danzliu94@gmail.com
https://beyond-md.co/
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "expects", "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things, management expectations that the Company will file the Annual Filings within the time period described herein.
These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the Company being unable to file the Annual Filings in the proposed timeframe; recent market volatility; and the state of the financial markets for the Company's securities.
In making the forward looking statements in this news release, the Company has applied several material assumptions, including without limitation, that: the Company will be able to file the Annual Filings in the proposed time frame.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250586
FAQ
Why did Beyond Medical Technologies (DOCKF) receive a management cease trade order in 2025?
When will Beyond Medical Technologies (DOCKF) file their 2024 annual financial statements?
What are the implications of the MCTO for Beyond Medical Technologies (DOCKF)?
What caused the delay in Beyond Medical Technologies' (DOCKF) 2024 annual filings?
